Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with I-MVAC in Advanced Urothelial Carcinoma
NCT02818725Phase 3Completed
- Sponsor
- Unicancer
- Start
- Jun 2010
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in urothelial carcinoma (UC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-Free Survival at 9 months. Started Jun 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02818725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818725.